Welcome to our dedicated page for Atlas Energy news (Ticker: CANSF), a resource for investors and traders seeking the latest updates and insights on Atlas Energy stock.
Atlas Energy Corp. (CANSF) generates news that reflects its role as an international upstream oil and gas royalty and streaming company and its evolution from Willow Biosciences Inc. Company announcements have described a significant recapitalisation, the completion of a TSX Venture Exchange listing under the symbol ATLE, and changes to its trading status on U.S. over-the-counter markets.
Earlier news releases issued under Willow Biosciences Inc. provide important background for investors tracking this symbol. Those disclosures cover the sale of Willow’s wholly owned operating subsidiary, the resulting status of Willow as having no active business, and the subsequent reorganization and investment agreement that provided for a private placement, new executive leadership, a reconstituted board of directors, and a name change to Atlas Energy Corp. They also outline the expected transition of the listing from the Toronto Stock Exchange to the TSX Venture Exchange and the use of the TSXV Sandbox program.
More recent communications under the Atlas Energy name highlight the company’s upstream royalty and streaming focus, the initial recapitalisation, and its status as a TSXV Sandbox issuer. News items also describe the voluntary delisting of the company’s common shares from the OTCQB and continued trading on the TSX Venture Exchange and OTC Pink market.
Investors following CANSF-related news can review this history to understand how the business focus shifted from precision fermented ingredients and biomanufacturing under Willow Biosciences to oil and gas royalty and streaming interests under Atlas Energy Corp., as well as how the company’s capital structure and listing venues have changed over time.
Nelnet (NYSE: NNI) announced that Tim Tewes, president of Nelnet and CEO of Nelnet Business Services, will retire in June 2026 after more than 25 years with the company. Tewes joined Nelnet in 2005 after the acquisition of FACTS Management, became CEO of NBS in 2007 and assumed the role of Nelnet president in 2014. The release notes Tewes led strategic acquisitions, expanded product offerings, and helped establish FACTS and Nelnet Campus Commerce as market leaders in education payment solutions. Nelnet also highlighted Tewes' role in launching Nelnet Bank. Tewes will continue to serve on the Nelnet Bank Board of Directors.
Atlas Energy Corp. (OTC:CANSF) has announced the completion of a significant $30 million recapitalization during Q2 2025. The company, now listed as a TSXV Sandbox issuer under the symbol ATLE, has voluntarily delisted from OTCQB while maintaining trading on the OTC Pink platform for U.S. investors.
The company has positioned itself as an international upstream royalty and streaming company focused on oil and gas interests across global markets. CEO Mark Hodgson highlighted strong institutional investor support for the company's experienced team and disciplined strategy. As a TSXV Sandbox listing, Atlas must meet specific exit conditions, though there's no guarantee of meeting these requirements.
Willow Biosciences has completed the sale of its operating subsidiary, Epimeron USA, to Mycofeast's U.S. subsidiary for US$2.76 million in cash. The transaction includes an escrow amount of US$275,975 held until September 17, 2025, subject to potential adjustments and indemnity claims.
Following the sale, significant management changes have occurred: CEO Dr. Chris Savile and SVP of Research and Development Dr. Trish Choudhary have resigned to join the purchaser. CFO Travis Doupe has been appointed as Interim CEO.
The company plans to use part of the proceeds for debt reduction while retaining the remainder pending a review of future cash requirements and potential opportunities. The transaction was executed through a share purchase agreement dated March 14, 2025, with detailed information available in the company's management information circular on SEDAR+.
Willow Biosciences (TSX: WLLW, OTCQB: CANSF) held its annual general and special meeting on April 25, 2025, with 40.88% shareholder participation representing 59,214,893 common shares. Key approvals included:
- Election of 5 directors with strong majority support (84.5-88.4% approval): Dr. Chris Savile, Dr. Jim Lalonde, Donald Archibald, Raffi Asadorian, and Al Foreman
- Appointment of KPMG LLP as auditor (87.6% approval)
- Sale of Epimeron USA subsidiary (88.4% approval)
- Authorization for potential company name change to '2482118 Alberta ' (82.5% approval)
Willow Biosciences (TSX: WLLW, OTCQB: CANSF) has announced its financial results for 2024 and provided an update on the sale of its operating subsidiary. The company currently faces a working capital deficit of approximately CDN$180,000 excluding lease liabilities.
The company has entered into an agreement to sell its wholly-owned operating subsidiary, Epimeron USA, to a private UK-based entity for US$3.38 million in cash. Of this amount, US$900,000 will be held in escrow subject to adjustments. After anticipated adjustments, transaction costs, severance payments, and debt repayment, Willow expects to retain approximately CDN$1.1 million in cash.
Following the transaction, Willow will likely not meet TSX listing requirements and will undergo an expedited review process. The company will terminate key executives, including CEO Dr. Chris Savile and SVP of Research Dr. Trish Choudhary, as it will cease active operations.
Willow Biosciences (TSX: WLLW, OTCQB: CANSF), a biotechnology company focused on sustainable ingredient manufacturing, has announced the initiation of a formal strategic review process. The decision comes after unsuccessful attempts to secure financing under favorable shareholder terms amid challenging capital market conditions.
The strategic alternatives under consideration include:
- Sale of all or part of Willow's business and assets
- Complete company sale
- Merger with a third party
- Joint ventures
- Royalty or licensing arrangements
- Introduction of new strategic shareholders
- Various financing alternatives
The company has established a virtual data room for interested parties to review information upon signing a confidentiality agreement. While no definitive timeline has been set, management believes this process will benefit shareholders. The company does not plan to provide regular updates unless necessary or until a definitive transaction is approved.
Willow Biosciences (TSX: WLLW, OTCQB: CANSF) reported record Q3 2024 revenue of $1.7 million, up from $674,000 in Q3 2023. The company signed a commercial license and royalty agreement with Kalsec, expecting milestone and tiered royalty payments. Willow also partnered with an Ag-Biotech company for a biopesticide strain, projected to generate $2 million in revenue. Additionally, Willow completed its first program with a leading API manufacturer and signed a second program to develop a large volume ingredient. The company raised $1.6 million through a private placement and increased its 2024 revenue guidance to over $4.5 million. Despite these advancements, Willow reported a net loss of $1.2 million for Q3 2024, an improvement from a $2.2 million loss in Q3 2023. The company expects further growth with 1-2 new partnerships by year-end 2024.
Willow Biosciences (TSX: WLLW, OTCQB: CANSF) has partnered with a global ingredient manufacturer to develop, scale, and commercialize a high-value ingredient from its internal portfolio. The collaboration includes R&D payments of up to $1.3 million and a 15-year tiered profit share arrangement. The 12-month research program targets a $1 billion global market segment currently dominated by chemically synthesized products. Willow aims to develop a high-purity, sustainable, bio-identical natural ingredient expected to be more cost-effective than chemical alternatives. The partner will handle regulatory compliance, manufacturing, and marketing responsibilities.
Willow Biosciences (TSX: WLLW; OTCQB: CANSF) has announced a second collaboration with a leading Active Pharmaceutical Ingredient (API) manufacturer. This new program aims to develop an optimized enzyme for large-scale manufacturing of a high-volume API used in a therapeutic with a global market exceeding $1 billion. The development phase is expected to last about six months, with potential milestone payments achievable by 2025. This marks Willow's 4th commercial agreement this year with potential milestone payments as early as next year. The collaboration builds on the success of their first program announced in January 2024, where Willow has already met certain development goals.